Ozempic may be the obesity drug that seems to be ubiquitous in the news, but it is not the only obesity drug therapy on the market or in production. 4 companies stand to dominate the obesity market and estimates have them controlling around 83% of the total market by 2032:
Eli Lilly (LLY)
Novo Nordisk (NVO)
Amgen (AMGN)
Pfizer (PFE)
In case you were wondering what the economics for these drugs might look like:
The average global price of GLP-1 therapy for obesity is forecast to rise to roughly $5,400 a year and then gradually decline beginning in 2025 as competing therapies launch, falling to roughly $2,800 by 2032. Forecasts have the market growing to ~$60B by 2032 across all companies with a target of over 20M patients.